Posts in Digital Therapeutics/SaMD
Digital Therapeutics Alliance Summit 2024: 5 Takeaways for DTx Innovators

The Digital Therapeutics Alliance Summit 2024, held in Washington, D.C., brought together over 500 industry leaders (including NGL’s own Carrie Nixon and Michael Schellhous), innovators, and key stakeholders to discuss the current state and future of digital therapeutics (DTx). 

Read More
[video] Digital Health Innovators: Does your solution qualify as Software as a Medical Device (SaMD)?

If you’re in the Remote Patient Monitoring (RPM) or Remote Therapeutic Monitoring (RTM) space, then you’ll want to understand the criteria and opportunities for qualifying as Software as a Medical Device (SaMD)

Read More
**Video Post** MedTech Study: NGL & UCLA Biodesign

The UCLA Biodesign Hub for MedTech and Digital Health (UCLA Biodesign) is seeking executives from medical technology and digital health companies to participate in a new study focused on advancing regulatory and reimbursement for innovative technologies. This study aims to establish benchmarks, educate regulators, and potentially influence future decision-making at a local and national level. In furtherance of increasing our healthcare system’s capacity to deliver MedTech and digital health innovations to patients and providers, we invite you to participate in UCLA Biodesign’s landmark study, Innovation in MedTech and Digital Health: A New Decade!

Read More
Breakthrough Devices: CMS Removes Hurdles and Increases Payments for New Technology Add-On Payments Under the IPPS Final Rule

Hospitals and medical device manufacturers will both benefit from the Centers for Medicare and Medicaid Services’ (CMS) finalization of the 2020 Inpatient Prospective Payment System (IPPS) Final Rule (“Final Rule”) scheduled to be published on August 16, 2019.  In an effort to increase Medicare beneficiaries’ access to innovative medical technologies, CMS has finalized certain changes to the “new technology add-on payment” “(NTAP) application and payment processes under the Final Rule. This change is likely to encourage hospital adoption of new technologies, which is intended to spur innovation and additional investment in these technologies.

Read More